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Background: The objective of this retrospective study is to investigate laryngeal preservation and long-term
treatment results in hypopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) combined
with chemotherapy.
Methods: Twenty-seven patients with hypopharyngeal carcinoma (stage II-IV) were enrolled and underwent
concurrent chemoradiotherapy. The chemotherapy regimens were monthly cisplatin and 5-fluorouracil for six
patients and weekly cisplatin for 19 patients. All patients were treated with IMRT with simultaneous integrated
boost technique. Acute and late toxicities were recorded based on CTCAE 3.0 (Common Terminology Criteria for
Adverse Events).
Results: The median follow-up time for survivors was 53.0 months (range 36-82 months). The initial complete
response rate was 85.2%, with a laryngeal preservation rate of 63.0%. The 5-year functional laryngeal, local-regional
control, disease-free and overall survival rates were 59.7%, 63.3%, 51.0% and 34.8%, respectively. The most common
greater than or equal to grade 3 acute and late effects were dysphagia (63.0%, 17 of 27 patients) and laryngeal
stricture (18.5%, 5 of 27 patients), respectively. Patients belonging to the high risk group showed significantly
higher risk of tracheostomy compared to the low risk group (p = 0.014).
Conclusions: After long-term follow-up, our results confirmed that patients with hypopharyngeal carcinoma
treated with IMRT concurrent with platinum-based chemotherapy attain high functional laryngeal and local-
regional control survival rates. However, the late effect of laryngeal stricture remains a problem, particularly for high
risk group patients.
Background
Patients with resectable, locally advanced laryngeal and
hypopharyngeal carcinoma have historically been treated
with surgery and adjuvant radiotherapy [1-3]. However,
their quality of life is greatly impaired because the entire
larynx is sacrificed. After the finding by VA Laryngeal
Cancer Study Group [4] that induction chemotherapy
followed by definitive radiotherapy leads to a larynx
preservation rate of 68%, this method has been consid-
ered as an organ preservation treatment for laryngeal
carcinoma [5-8]. The European Organization for
Research and Treatment of Cancer (EORTC) conducted
a phase III study for hypopharyngeal carcinoma aimed
at laryngeal preservation (EORTC 24891) showing that
treatment with induction chemotherapy and radiother-
apy yields comparable local and overall survivals to
treatment with surgery and adjuvant radiotherapy [5].
The Southwest Oncology Group designed a phase II
trial for patients with cancer of the base of the tongue
or hypopharynx aimed at organ preservation [7].
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selected patients with more than 50% response were
given concurrent chemo-radiotherapy. Their results
showed that 75% of patients did not require surgery for
the primary tumor. With the success of induction che-
motherapy and radiotherapy for laryngeal preservation
while maintaining local control and survival for laryn-
geal or hypopharyngeal carcinoma, other studies on the
efficacy of concurrent chemotherapy have been con-
ducted, such as the Radiation Therapy Oncology Group
(RTOG) study 91-11 [9]. That study evaluated the laryn-
geal preservation rates at 2 years, and the preservation
rate in the concurrent chemoradiotherapy group (88%)
was significantly higher than that in the induction che-
motherapy followed by radiotherapy group (75%, p =
0.005) and the radiotherapy alone group (70%, p <
0.001) [9]. However, the major concern with the concur-
rent chemoradiotherapy approach is profound acute
side-effects [9,10]. Hence, the EORTC (24954) designed
a protocol of alternating chemotherapy and radiotherapy
to compare sequential treatments [11].
More recently, intensity-modulated radiotherapy
(IMRT) has been adopted for reduction of treatment
related side-effects in head and neck cancer patients
[12-17]. Dosimetry studies have confirmed that IMRT
method can deliver more precise dose distribution
around the target(s) and maintain lower doses to critical
nearby organs [18,19]. Clinical studies of nasopharyngeal
cancer patients treated with IMRT confirm that this
technique reduces the degree of xerostomia while main-
taining and even increasing local control of this disease
[13,20]. Although there is widespread application of
IMRT for head and neck tumor, only a few studies have
reported the effectiveness of laryngeal preservation and
treatment outcomes of hypopharyngeal cancer treated
with this new technology [21,22]. Moreover, these stu-
dies had a relatively short follow-up period. For exam-
ple, the median follow-up time in Lee’s study was 26
months [22]. To properly evaluate the role of IMRT in
this disease, it is very important to understand the long-
term results, including both the laryngeal preservation
survival and late complications for hypopharyngeal car-
cinoma. Therefore, the primary purpose of this retro-
spective study is to investigate the long-term
effectiveness of laryngeal preservation and treatment
outcomes in hypopharyngeal carcinomas treated with
IMRT and concomitant chemotherapy. The secondary
purpose is to evaluate the severity of late toxicities cor-
related with this treatment.
Methods
Patients and staging
Between May 2001 and February 2005, a single cohort
of 27 consecutive men (mean age 60.7 years; age range
42 to 85 years) with previously untreated stage II-IV
squamous cell carcinoma of hypopharynx were included
in this study. All patients had histological proved disease
and had refused surgical management or had initially
unresectable disease. None had a previous or synchro-
nous malignancy. Their disease was staged according to
the 2002 classification of the American Joint Committee
on Cancer. The distribution of T and N status are listed
in Table 1. Five patients had stage II disease, four
patients had stage III disease, sixteen patients had stage
IVa disease, and two patients had stage IVb disease.
Medical histories were reviewed, and all patients
underwent physical examination, laryngoscopic assess-
ment, analysis of complete blood count, blood biochem-
istry testing, chest radiography, computerized
tomography or magnetic resonance imaging (MRI), and
dental evaluation. Informed consent was obtained from
all patients before receiving treatment, and this study
was approved by the Institutional Review Board of
Chung Shan Medical University Hospital.
Radiotherapy
All patients were treated in the supine position with the
use of immobilization masks and rigid pillows to sup-
port the neck (MT-201-D, MEDTEC Inc.). With com-
puterized tomographic simulator (GE HiSpeed Fx, GE
Inc.) series images of 3-mm per section were acquired.
The definitions of gross target volume (GTV), clinical
target volume (CTV), and planning target volume (PTV)
followed those of the International Commission on
Radiation Units and Measurements, ICRU report 62
[23]. The PTV-1 and PTV-2 were extended from GTV
and CTV three-dimensionally with 5 mm and 3 mm
margins, respectively. All patients received two stages of
radiotherapy; the first stage was composed of PTV-1
and PTV-2 and the second stage only covered PTV-1
for boosting the gross tumor. This treatment plan was
considered acceptable if more than 99% volume of PTV-
1a n d9 8 %v o l u m eo fP T V - 2c o u l db ec o v e r e db yt h e
prescribed dose. In the first stage of treatment, PTV-1
w a st r e a t e dw i t had o s eo f6 3 . 6G yi n3 0f r a c t i o n sf o r
T2-T3 lesions and 67.8 Gy in 32 fractions for T4
Table 1 Tumor and lymph node classifications of study
participants
Node Stage
Tumor Stage N0 N1 N2 N3
T2 (n = 8) 5 1 1 1
T3 (n = 6) 2 1 3 0
T4 (n = 13) 1 2 8 2
Total (n = 27) 8 4 12 3
*Tumor and nodes were staged according to the 2002 classification of the
American Joint Committee on Cancer Staging.
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grated boost (SIB) in the treatment plan [18]. The frac-
tion sizes for PTV-1 and PTV-2 were 2.12 Gy and
1.75~1.8 Gy, respectively. In the second stage of treat-
ment, PTV-1 was planned for another 9.0 Gy in five
fractions. With the above two stages, the planned total
doses to PTV-1 for T2-3 and T4 cases were 72.6 Gy in
35 fractions and 76.8 Gy in 37 fractions, respectively.
Hence, the total doses to PTV-2 were 54 Gy and 56 Gy
for T2-3 and T4 diseases, respectively. All treatment
plans were calculated by Helio treatment planning sys-
tem (Varian Oncology Systems, Palo Alto, CA). Accord-
ing to a study by Wu [12], the fine-tuning of beam
angles is not important in IMRT, in contrast to standard
radiotherapy, as long as a sufficient number of beam
angles are used. Therefore, we defined seven gantry
angles arbitrarily. They are 20°, 70°, 125°, 175°, 220°,
275°, and 325°. Twenty segments of each treatment field
were set with step-and-shot method. Then, the intensity
distributions within the treatment fields were optimized
to gratify constraints of different normal tissues and tar-
gets like mentioned above. Treatment was delivered
using a dynamic multileaf collimator system (Varian
Oncology Systems, Palo Alto, CA).
Elective irradiation of regional lymph nodes was
designed using the same principles in all cases. These
lymphatic areas, including in the CTV, were bilateral
levels of Ib, II, III, IV, and V, plus central area of VI, as
defined by the American Joint Committee on Cancer.
The bilateral retropharyngeal lymph nodes were also
included in the CTV volume. Bilateral supraclavicular
treatment field was defined as PTV-3 and arranged by
an anterior-posterior portal. When treating this supra-
clavicular treatment field, we did not use a central block
to protect the spinal cord until the dose accumulated to
43.2 Gy in 24 fractions. Then, this field was further irra-
diated to 48.6 to 52.2 Gy in 27 to 29 fractions with cen-
tral shielding. Same iso-center and positioning setup
was used for both supraclavicular (PTV-3) and IMRT
fields (PTV-1 and PTV-2) in order to minimize junction
errors between them. The constraints of nearby organs
were spinal cord maximum lower than 45 Gy, ipsilateral
parotid gland mean dose lower than 30 Gy, and contral-
ateral parotid gland lower than 26 Gy. If the tumor
extended near to or invaded the vocal cords, no specific
protection to this region was planned. Otherwise, we
tried to restrict the dose to opposite vocal cord to below
60 Gy.
Chemotherapy
All patients received concomitant chemoradiotherapy.
Early in the study, six patients received two courses of
chemotherapy during radiotherapy. Their regimen was
cisplatin 60 mg/m
2 on days 1 and 29, and 5-fluorouracil
600 mg/m
2 on days 1-4 and 29-32. This regimen
resulted in profound pharyngitis and esophagitis, thus
the remaining 21 patients received cisplatin 30 mg/m
2/
week for 7 weeks.
Treatment evaluation and follow-up
During treatment, patients were examined weekly. After
treatment was completed, patients were evaluated every
month for the first year, every 3 months for the second
and third years, and every 6 months until last follow-up.
Follow-up time was defined as the start of radiotherapy
to May 2008. The treatment response of the primary
tumor was evaluated by means of both fiberscope laryn-
goscope and MRI examination two to three months
after completion of radiotherapy. Then, fiberscope laryn-
goscope was performed every three months for the first
two years, and every 6 months until last follow-up. MRI
examination was done annually until last follow-up.
Seven patients were evaluated by FDG PET scan about
five to six months after treatment. The definition of
residual or recurrent disease was judged by both fiber-
scope laryngoscope and MRI examination. The complete
response was defined by clinical assessment and tissue
biopsy was carried out if there was any uncertainty. The
acute and late adverse effects were graded according to
the criteria of CTCAE 3.0 [24].
Statistical analysis
Functional laryngeal, local-regional progression-free, dis-
ease-free, and overall survival rates were calculated
using the Kaplan-Meier method. To evaluate the feasi-
bility and toxicity of IMRT treatment modality we eval-
uated the risk factors for grade-3 late toxicity. The
Fisher exact test was used to evaluate the correlation
between toxicity scales (including tracheostomy) and
potential risk factors such as T-stage (T2-3 vs. T4),
GTV dose (less than 76 Gy vs. more than 76 Gy), gross
tumor volume (less than 37 ml vs. more than 37 ml),
primary tumor location (pyriform sinus vs. other sites)
and chemotherapy regimens (cisplatin alone vs. cisplatin
plus 5-fluorouracil), respectively. To evaluate any poten-
tial risk group that may correlate of receiving tracheost-
omy during or after this treatment, we separated our
patients into two risk groups based on below definitions.
We defined the high risk group as possessing two to
three of the following factors: GTV dose more than 76
Gy, gross tumor more than 37 ml and primary tumor
location other than pyriform sinus. Those without or
just one of the above factors were defined as low risk
group. The Fisher exact test was used to evaluate the
correlation between tracheostomy and the high risk
group. The Log Rank test was used to evaluate the func-
tional laryngeal survival difference between high and low
risk groups. Statistical significance was set at p < 0.05.
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Doses to targets and critical tissues
The mean total doses to PTV-1, PTV-2 and PTV-3 were
76.2 Gy, 60.6 Gy and 51.3 Gy, respectively. Table 2 pre-
sents the mean doses to targets and important sur-
rounding normal organs. All doses to targets and critical
organs were the summations of all treatment plans
including 3D CRT and IMRT.
Follow-up time
The median follow-up time was 36.0 months (range 2 to
82 months) for all patients, and 53.0 months (range 36
to 82 months) for survivors.
Treatment outcomes and laryngeal preservation
The functional laryngeal preservation rate was 63.0% (17
of 27 patients) up to the last follow-up (May 2008). The
complete response rate after treatment was 85.2% (23 of
27 patients). Three patients had persistent disease at the
primary sites and two patients at the neck lymph nodes,
o n eo ft h e mh a dp e r s i s t e n td i s e a s ea tb o t hs i t e s .U pt o
the last follow-up, four patients had primary recurrence.
Of those patients, three had disease at the primary site
and one had disease at both the primary site and neck
lymph nodes. The functional laryngeal, local-regional
progression-free, disease-free, and actuarial overall survi-
val rates at 3 years were 59.7%, 68.2%, 63.7%, and 51.9%,
respectively. The functional laryngeal, local-regional pro-
gression-free, disease-free, and actuarial overall survival
rates at 5 years were 59.7%, 63.3%, 51.0%, and 34.8%,
respectively (Figures 1, 2, 3 and 4).
Two patients received salvage surgery for local-regio-
nal failure: one due to persistent disease (primary site
and lymph neck nodes) and the other due to primary
recurrence 13 months after radiotherapy. At the last fol-
low-up, these two patients were still alive without evi-
dence of recurrence. Regarding distant metastases, three
patients had lung metastases 13 to 33 months after
treatment and three patients had bone metastases 5 to
58 months after treatment. Two patients developed sec-
ondary malignancies, including gastric and colon cancer
10 and 17 months after radiotherapy, respectively. One
patient received radical surgery. At the last follow-up,
one of these two patients was alive without evidence of
disease while the other had died of gastric cancer.
Adverse effects
Table 3 lists the sites and grades of the acute and late
effects. The most common site of greater than or equal
to grade 3 acute side-effects was the dysphagia (63.0%,
17 of 27 patients). The most common site of greater
than or equal to grade 3 late effects was the larynx
(stricture) (18.5%, 5 of 27). There were no significant
correlations between greater than or equal to grade 3
late laryngeal toxicity and T4 stage (p = 0.62), GTV
dose greater than 76 Gy (p = 0.27), volume of gross
tumor greater than 37 ml (p = 0.19) or location of the
primary tumor (p = 0.61). When we evaluated the corre-
lation between the ratio of this late effect and the risk
groups, there was significant difference (p = 0.014)
between the high (5 of 8 patients) and low risk groups
(2 of 16 patients) on Fisher exact test. However, there
was no significant difference in functional laryngeal sur-
vival between these two groups (p = 0.055, figure 5).
The ratios of greater than or equal to grade 3 acute
toxicity of the pharynx for the monthly regimen of cis-
platin plus 5-fluorouracil and the weekly regimen of cis-
platin were 83.3% (5 of 6 patients) and 47.6% (10 of 21
patients), respectively. However, the difference was not
statistically significant (p = 0.277). Sixteen patients
(59.3%) required nasogastric-tube feeding during the
treatment while seven patients (25.9%) required a tra-
cheostomy due to stridor. However, only two of them
(2/7) could reverse from tracheostomy to normal
breathing at three and six months, respectively.
One patient (3.7%) died of pharyngeal late effects 10
months after treatment due to aspiration pneumonia
caused by severe pharyngeal stricture and poor swallow-
ing function. This patient had T2N3M0 disease and had
received chemotherapeutic regimen of weekly cisplatin.
The radiation doses to primary tumor and neck lymph
nodes were 76.2 and 77.5 Gy, respectively.
Discussion
Patients with hypopharyngeal carcinoma usually have
functional and cosmetic sequelae after surgery. There-
fore, any attempt to preserve the larynx while achieving
the treatment outcomes equal to surgical results is war-
ranted. Most studies of laryngeal preservation have
included hypopharyngeal carcinoma, as well as carcino-
mas of the tongue base, oropharynx, and larynx
Table 2 Doses to targets and critical organs in larynx-






PTV-1* 76.2 70.1–82.7 2.12/33-37
PTV-2* 60.6 54.7–67.2 1.75-1.8/34-37
PTV-3* 51.3 48.6-57.6 1.8/27-32
Spinal Cord§ 49.1 39.3–60.6
Spinal Cord† 44.5 36.2–50.0
Parotid Gland, ipsilateral 34.1 23.3–46.6
Parotid Gland, contralateral 30.5 18.7–44.7
* PTV-1, planning target volume of gross tumor; PTV-2, planning target
volume of clinical target volume; PTV-3, planning target volume of bilateral
supraclavicular fossa.
§Maximal dose to the spinal cord.
†Five percent volume dose to the spinal cord.
** Daily dose and fraction numbers in IMRT treatment.
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Page 4 of 10Figure 1 Functional larynx survival rates at 3 years and 5 years were 59.7% and 59.7%, respectively.
Figure 2 Local-regional progression-free survival rates at 3 years and 5 years were 68.2% and 63.3%, respectively.
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Page 5 of 10Figure 3 Disease-free survival rates at 3 years and 5 years were 63.7% and 51.0%, respectively.
Figure 4 Overall survival rates at 3 years and 5 years were 51.9% and 34.8%, respectively.
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Page 6 of 10[6,7,25,26]. To our knowledge, with median follow-up
time of 53.0 months (range 36 to 82 months); this is the
longest follow-up of the clinical experience of IMRT
concurrent with chemotherapy for hypopharyngeal can-
cer so far. The importance of long-term follow-up is to
evaluate the late effect and laryngeal preservation rate of
IMRT treatment.
The proportion of severe acute toxicity with concomi-
tant chemoradiotherapy is expected to be higher than
that of radiotherapy alone [9,10,27]. In this study, the
most common greater than or equal to grade 3 acute
side effects was dysphagia (17 of 27 patients, 63.0%). In
Lee’s report, all patients experienced grade 2 pharyngitis
[22], and all patients received feeding tubes via percuta-
neous endoscopic gastrostomy (PEG) (prophylactic in 30
and during treatment in one). Thus, it is difficult to
evaluate the true acute dysphagia grading from their ser-
ies. As for the late effect causing more than grade 3 dys-
phagia, De Arruda et al. reported their experience of
IMRT treatment for oropharyngeal cancer [28]. They
performed PEG prior to radiotherapy for 42 of
50 patients (84%) and during radiotherapy for 6 (12%).
Eisbruch et al. demonstrated that the sparing of pharyn-
geal constrictor muscle, supraglottic larynx and glottic
larynx can reduce the complication of late dysphagia for
Table 3 Acute and late adverse effects of larynx-
preservation treatment of hypopharyngeal carcinoma
Grade
Site and Effect 0 1 2 ≥3†
Skin
Acute, dermatitis 3 9 11 3
Late, telangiectasia 14 6 4 1
Late, fibrosis 9 11 4 1
Mucositis
Acute, oral cavity 0 4 13 9
Pharynx/esophagus
Acute, dysphagia 0 1 9 17
Late, stricture 2 15 5 1
Larynx
Acute, edema 0 4 14 8
Late, stenosis 3 13 4 5
Xerostomia
Acute 0 11 13 2
Late 1 12 11 1
Myelitis
Late 24 3 0 0
* The acute and late adverse effects were graded according to the scoring
criteria of the CTCAE 3.0 [24].
† All effects were grade 3, with the exception of the grade 5 late effects in
the pharynx/esophagus.
Data are given as number of incidences.
Figure 5 Functional larynx survival rates of the high and low risk groups at 5 years were 22.5% and 72.5%, respectively. The high risk
group was defined as those possessing two or more factors including GTV dose of more than 76 Gy, gross tumor more than 37 ml and/or
primary tumor location other than pyriform sinus. The low risk group was defined as those with one or none of the above factors.
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que [29]. From our study, the mean dose to the above-
mentioned three anatomical structures was 60.6 Gy
(PTV-2) unless gross tumor presented within these
areas. The incidence of grade 3 acute dysphagia was
relatively high, 16 patients needed NG tube and one
patient refused NG tube or PEG insertion. Fortunately,
this acute adverse effect was manageable, and fifteen of
o u rp a t i e n t sw e r ea b l et oh a v et h eN Gt u b er e m o v e d
one to six months after completion of treatment. Using
IMRT for protection of normal tissue from extensive
radiation damage, there was only one long-term survivor
(3.7%) who suffered from grade 3 late dysphagia caused
by pharyngo-esophageal stricture. However, the inci-
dence of late dysphagia may be underestimated due to
some patients died early from disease, and thus there
may not have been enough time to develop late effect.
With careful monitoring and management of all acute
treatment side effects, no patient died of acute reaction
or complication during this multi-modality aggressive
treatment.
Few studies have addressed acute or late effects of
stridor caused by laryngeal edema or stricture, respec-
tively. Recently, Nangia et al. reported results of 83 head
and neck cancers treated by IMRT method [30]. In their
series, hypopharyngeal cancer was present in 13 and lar-
yngeal cancer in 35 patients. Concerning tracheostomy,
t h e r ew e r ef i v ep a t i e n t si nw h o mt h i sp r o c e d u r ew a s
performed before irradiation and eight patients in who
it was performed after irradiation. Among these 13
patients who received tracheostomy, there were 5
patients with closure after the completion of treatment.
However, they did not evaluate the risk factors for pre-
dicting this adverse effect. In our study, seven patients
needed tracheostomy during or within 3 months after
CCRT, and only two of them could closure thereafter. It
is imperative to perform tracheostomy surgery when
there is grade 3 acute/late laryngeal strictures. Due to
low reversibility of this side-effect, we attempted to eval-
uate the predictive value of risk factors that may corre-
late to this late effect. These potential risk factors
included T4-stage (p = 0.62), GTV dose greater than 76
Gy (p = 0.274), volume of gross tumor greater than 37
ml (p = 0.19) and location of primary tumor other than
the pyriform sinus (p = 0.61). However, we did not yield
any meaningful results between these risk factors and
the ratio of late laryngeal stricture. Interestingly, if we
divided our patients into high and low risk groups, sig-
nificant differences (p = 0.014) were found for the ratio
of tracheostomy. The definition of the high risk group
was those possessing two to three of the following fac-
tors: GTV dose more than 76 Gy, gross tumor more
than 37 ml and primary tumor location other than pyri-
form sinus. Those without or only one of the above risk
factors were defined as low risk group. When we evalu-
ated the functional laryngeal survival between these two
groups, there was no significant difference (p = 0.055,
Figure 5). However, the trend of better functional laryn-
geal survival for low risk group was clearly
demonstrated.
As this is only a retrospective study, any attempt to
compare our survival data with randomized trials is dif-
ficult or even impossible. We list recently studies that
focused on the organ preservation for hypopharyngeal
cancer in Table 4. Only a few studies have focused on
laryngeal preservation by IMRT for hypopharyngeal car-
cinoma [21,22]. The earliest clinical experience of IMRT
for head and neck tumor is for nasopharyngeal carci-
noma [13]. Lee et al. conducted one of the first clinical
studies to focus on laryngeal preservation with IMRT
technique for laryngeal (20 cases) and hypopharyngeal
(11 cases) carcinoma [22]. They found that the 2-year
local progression free survival rate is 86% with accepta-
ble acute side-effects. Thiss t u d ys h o w st h a tS I B - I M R T
and concomitant chemotherapy is highly effective in the
treatment of hypopharyngeal carcinoma. After a median
Table 4 Results of treatment in hypopharyngeal cancer with organ preservation approach
Author Methods No. LCS (yr) DFS (yr) OS (yr) LPS (yr)
Lefebvre[5] Surgery 94 31% (3) 43% (3) -
IC + RT 100 43% (3) 57% (3) 42% (3)
Zelefsky[8] IC + RT 26 30% (5) 15% (5) 52% (5)
Surgery 30 42% (5) 22% (5)
Altundag[6] IC + RT 45 total (5 hypo.) 50.9% (2) 63.3% (2)
Urba[7] IC + RT 59 total (22 hypo.) 64% (3) 52% (3)
Lee [22] CCRT 31 (11 hypo.) 94% (2) 86% (2) 63% (2) 89% (2)
Lefebvre[11] IC + RT 224 (116 hypo.) 49.7% (3) 48.5% (5) 39.5% (5)
alternating 226 (115 hypo.) 50.6% (3) 51.9% (5) 45.4% (5)
This study CCRT 27 63.0% (5) 51% (5) 34.8% (5) 59.2% (5)
LCS: local control survival, DFS: disease-free survival, OS: overall survival, LPS: laryngeal preservation survival, IC: induction chemotherapy, RT: radiotherapy, hypo.:
hypopharynx, HF-ACC-RCT: hyperfractionated accelerated radiochemotherapy, HF-ACC-RT: hyperfractionated accelerated radiotherapy, CCRT: concurrent
chemoradiotheapy.
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laryngeal preservation was achieved in 17 of 27 patients
(63.0%). Local-regional control survival rates at 3 years
and 5 years were 68.2% and 63.3%, respectively. How-
ever, the 3- and 5-year disease-free survival rates (63.7%
and 51.0%) and overall survival rates (51.9% and 34.8%)
are not compatible with the survival rate of local-regio-
nal control. Our long-term follow-up results indicate
that even if local-regional control is stable after three
years, distant metastatic events and secondary primary
malignancy can impair overall survival over time. There-
fore, there exists the great challenge of reducing the
incidences of distant metastases and secondary malig-
nant disease among these patients.
Conclusions
The main concerns of this new treatment are feasibility
and toxicity. Our experience found that the most com-
mon grade 3 acute adverse effect is dysphagia. Fortu-
nately, this could be managed with medication and
nutritional support, e.g. insertion of NG tube. The most
common grade 3 late toxicity was laryngeal stricture.
This toxicity impairs both the functional laryngeal pre-
servation rate and survival. It is imperative to perform
tracheostomy surgery when there is grade 3 acute or
late laryngeal stricture. To prevent this late effect, our
study found that patients in the high risk group have
significantly higher risk of receiving tracheostomy. As
for tumor control and survival after this aggressive
CCRT protocol, our experience yielded high functional
laryngeal and local-regional control survival at 3- and
5-years. However, with long-term follow-up, the disea-
se-free survival and overall survival rates declined gradu-
ally despite high local-regional control survival. These
findings encourage further investigation of concurrent
chemo-radiotherapy with SIB-IMRT technique for hypo-
pharyngeal carcinoma both for laryngeal preservation
and disease control.
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